Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Wave Life Sciences Ltd.NASDAQ: WVE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $9.06M rose 83.0% year over year, ahead of the +42.8% change in trailing-twelve-month stock-based compensation.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 12.1 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +83.0% holds above the trailing-twelve-month pace of +42.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.06M— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$21.73M+42.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +42.8% is the 2nd highest of 10, against a peer median of +2.8%.
  • Stock-based compensation amounts to 30.3% of revenue for WVE, versus a peer median of 15.1%.
WVE Competitors
Stock-Based Compensation for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$336.62M USD+10.1%+14.7%7.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M USD+2.8%+19.1%220.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M USD+4.4%+10.1%13.8%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$111.37M USD-39.8%-19.1%5.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$68.15M USD+7.5%-4.5%15.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$26.2M USD-9.4%+12.2%81.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M USD-33.2%-6.0%50.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$21.73M USD+42.8%—30.3%
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026$12.56M USD+183.6%+171.6%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
Peer median (excluding WVE) —+2.8%+10.1%15.1%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
Deferred Income Tax(12.64M)0000
Stock-Based Compensation16.41M17.19M9.8M13.14M0
Change in Working Capital7.01M6.72M19.08M(75.82M)(16.94M)
Accounts Receivables30M0(21.09M)19.66M146K
Inventory2.04M0000
Accounts Payables(6.57M)9.35M(3.76M)3.42M(561K)
Other Working Capital(18.46M)(2.63M)43.93M(98.91M)(16.53M)
Other Non-Cash Items12.64M12K0024.97M
Operating Cash Flow(88.99M)(127.78M)(19.43M)(151.03M)(187.49M)
Capital Expenditures(560K)(1.36M)(1.12M)(938K)(718K)
Acquisitions (Net)00000
Purchases of Investments0(75.04M)000
Sales of Investments075.04M000
Other Investing Activities0106K000
Investing Cash Flow(560K)(1.26M)(1.12M)(938K)(718K)
Debt Repayment00000
Common Stock Issued54.97M52.33M131.28M236.18M488.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities858K14.86M1.26M17.71M0
Financing Cash Flow55.83M67.19M132.53M253.89M488.24M
Effect of Forex Changes(208K)(210K)(95K)(138K)12K
Net Change in Cash(33.93M)(62.06M)111.89M101.79M300.04M
Free Cash Flow(89.55M)(129.14M)(20.55M)(151.96M)(187.49M)

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.